Fortis Healthcare Limited’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025. Revenue from operations stood at ₹45,581 million for the quarter. The board also authorized a new operation and maintenance service deal with Gleneagles Healthcare India Private Limited, effective July 23, 2025, to oversee operations of five hospitals and one clinic.
Financial Performance Highlights
The Board of Directors of Fortis Healthcare Limited has officially approved the unaudited standalone and consolidated financial results for Q2 2026. Key financial figures include:
- Revenue from Operations (Standalone):₹45,581 million for the quarter.
- Total Income (Standalone):₹54,823 million for the quarter.
- Net Profit (Standalone):₹12,509 million for the quarter.
- Total Comprehensive Income (Standalone):₹12,504 million for the quarter.
- Revenue from Operations (Consolidated):₹233,144 million for the quarter.
- Total Income (Consolidated):₹235,402 million for the quarter.
- Net Profit (Consolidated):₹32,882 million for the quarter.
- Total Comprehensive Income (Consolidated):₹33,508 million for the quarter.
Strategic Business Decisions
In addition to the financial results, the board has sanctioned several key strategic initiatives:
- Entered into an operation and maintenance service agreement with Gleneagles Healthcare India Private Limited, effective July 23, 2025, to manage the operations of five hospitals and one clinic.
- International Hospital Limited (IHL) has executed a sub-lease agreement with R.R Lifesciences Pvt. Ltd (RRLPL) for sub leasing of Hospital land, building and equipment to IHL situated at Gautam Buddha Nagar, Greater Noida, effective September 1, 2025 and operations has commenced.
Ongoing Legal and Regulatory Matters
The company continues to address legacy legal and regulatory challenges, including investigations by the Serious Fraud Investigation Office (SFIO) and matters related to erstwhile promoters. Fortis maintains a strong commitment to cooperating with regulatory authorities and pursuing legal recourse where appropriate. Specifically, Fortis is diligently working to recover funds and ensure compliance with regulatory directives while safeguarding shareholder interests.
Source: BSE
